DNLI
Price
$16.99
Change
+$0.18 (+1.07%)
Updated
Dec 24 closing price
Capitalization
2.65B
66 days until earnings call
Intraday BUY SELL Signals
RARE
Price
$34.58
Change
+$0.45 (+1.32%)
Updated
Dec 24 closing price
Capitalization
3.34B
48 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

DNLI vs RARE

Header iconDNLI vs RARE Comparison
Open Charts DNLI vs RAREBanner chart's image
Denali Therapeutics
Price$16.99
Change+$0.18 (+1.07%)
Volume$505.01K
Capitalization2.65B
Ultragenyx Pharmaceutical
Price$34.58
Change+$0.45 (+1.32%)
Volume$721.61K
Capitalization3.34B
DNLI vs RARE Comparison Chart in %
DNLI
Daily Signal:
Gain/Loss:
RARE
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
DNLI vs. RARE commentary
Dec 26, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DNLI is a Hold and RARE is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Dec 26, 2025
Stock price -- (DNLI: $16.99 vs. RARE: $34.58)
Brand notoriety: DNLI and RARE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: DNLI: 32% vs. RARE: 51%
Market capitalization -- DNLI: $2.65B vs. RARE: $3.34B
DNLI [@Biotechnology] is valued at $2.65B. RARE’s [@Biotechnology] market capitalization is $3.34B. The market cap for tickers in the [@Biotechnology] industry ranges from $117.47B to $0. The average market capitalization across the [@Biotechnology] industry is $2.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

DNLI’s FA Score shows that 0 FA rating(s) are green whileRARE’s FA Score has 0 green FA rating(s).

  • DNLI’s FA Score: 0 green, 5 red.
  • RARE’s FA Score: 0 green, 5 red.
According to our system of comparison, both DNLI and RARE are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DNLI’s TA Score shows that 3 TA indicator(s) are bullish while RARE’s TA Score has 5 bullish TA indicator(s).

  • DNLI’s TA Score: 3 bullish, 6 bearish.
  • RARE’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, RARE is a better buy in the short-term than DNLI.

Price Growth

DNLI (@Biotechnology) experienced а +1.07% price change this week, while RARE (@Biotechnology) price change was +4.13% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.88%. For the same industry, the average monthly price growth was +4.46%, and the average quarterly price growth was +55.39%.

Reported Earning Dates

DNLI is expected to report earnings on Mar 02, 2026.

RARE is expected to report earnings on Feb 12, 2026.

Industries' Descriptions

@Biotechnology (+2.88% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RARE($3.34B) has a higher market cap than DNLI($2.65B). DNLI YTD gains are higher at: -16.634 vs. RARE (-17.804). RARE has higher annual earnings (EBITDA): -483.37M vs. DNLI (-534.17M). DNLI has more cash in the bank: 848M vs. RARE (425M). RARE has less debt than DNLI: RARE (33.8M) vs DNLI (44.4M). RARE has higher revenues than DNLI: RARE (631M) vs DNLI (0).
DNLIRAREDNLI / RARE
Capitalization2.65B3.34B80%
EBITDA-534.17M-483.37M111%
Gain YTD-16.634-17.80493%
P/E RatioN/AN/A-
Revenue0631M-
Total Cash848M425M200%
Total Debt44.4M33.8M131%
FUNDAMENTALS RATINGS
DNLI vs RARE: Fundamental Ratings
DNLI
RARE
OUTLOOK RATING
1..100
5916
VALUATION
overvalued / fair valued / undervalued
1..100
93
Overvalued
97
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
97100
PRICE GROWTH RATING
1..100
5256
P/E GROWTH RATING
1..100
99100
SEASONALITY SCORE
1..100
909

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

DNLI's Valuation (93) in the Biotechnology industry is in the same range as RARE (97). This means that DNLI’s stock grew similarly to RARE’s over the last 12 months.

DNLI's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as RARE (100). This means that DNLI’s stock grew similarly to RARE’s over the last 12 months.

DNLI's SMR Rating (97) in the Biotechnology industry is in the same range as RARE (100). This means that DNLI’s stock grew similarly to RARE’s over the last 12 months.

DNLI's Price Growth Rating (52) in the Biotechnology industry is in the same range as RARE (56). This means that DNLI’s stock grew similarly to RARE’s over the last 12 months.

DNLI's P/E Growth Rating (99) in the Biotechnology industry is in the same range as RARE (100). This means that DNLI’s stock grew similarly to RARE’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
DNLIRARE
RSI
ODDS (%)
Bearish Trend 2 days ago
87%
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
74%
Bullish Trend 2 days ago
73%
Momentum
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
81%
MACD
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
85%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
75%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
84%
Bullish Trend 2 days ago
71%
Advances
ODDS (%)
Bullish Trend 4 days ago
76%
Bullish Trend 4 days ago
77%
Declines
ODDS (%)
Bearish Trend 8 days ago
82%
Bearish Trend 8 days ago
81%
BollingerBands
ODDS (%)
N/A
Bearish Trend 2 days ago
76%
Aroon
ODDS (%)
Bullish Trend 2 days ago
65%
Bullish Trend 2 days ago
68%
View a ticker or compare two or three
Interact to see
Advertisement
DNLI
Daily Signal:
Gain/Loss:
RARE
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FRDPX91.420.39
+0.43%
Franklin Rising Dividends A
MVSSX33.490.09
+0.27%
Victory Integrity Small-Cap Value R6
MIVIX30.210.05
+0.17%
Madison Large Cap I
NSDVX21.50N/A
N/A
North Star Dividend I
KGGAX16.68-0.01
-0.06%
Kopernik Global All-Cap A

DNLI and

Correlation & Price change

A.I.dvisor indicates that over the last year, DNLI has been loosely correlated with RGNX. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if DNLI jumps, then RGNX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DNLI
1D Price
Change %
DNLI100%
+1.07%
RGNX - DNLI
53%
Loosely correlated
+0.77%
AVBP - DNLI
52%
Loosely correlated
-0.13%
XENE - DNLI
52%
Loosely correlated
+1.06%
BEAM - DNLI
52%
Loosely correlated
+1.33%
NRIX - DNLI
51%
Loosely correlated
+0.36%
More

RARE and

Correlation & Price change

A.I.dvisor indicates that over the last year, RARE has been closely correlated with MREO. These tickers have moved in lockstep 70% of the time. This A.I.-generated data suggests there is a high statistical probability that if RARE jumps, then MREO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RARE
1D Price
Change %
RARE100%
+1.32%
MREO - RARE
70%
Closely correlated
+0.44%
XNCR - RARE
48%
Loosely correlated
-0.13%
RGNX - RARE
47%
Loosely correlated
+0.77%
DNLI - RARE
47%
Loosely correlated
+1.07%
VCYT - RARE
46%
Loosely correlated
-0.35%
More